2022
Association between primary or booster COVID-19 mRNA vaccination and Omicron lineage BA.1 SARS-CoV-2 infection in people with a prior SARS-CoV-2 infection: A test-negative case–control analysis
Lind M, Robertson A, Silva J, Warner F, Coppi A, Price N, Duckwall C, Sosensky P, Di Giuseppe E, Borg R, Fofana M, Ranzani O, Dean N, Andrews J, Croda J, Iwasaki A, Cummings D, Ko A, Hitchings M, Schulz W. Association between primary or booster COVID-19 mRNA vaccination and Omicron lineage BA.1 SARS-CoV-2 infection in people with a prior SARS-CoV-2 infection: A test-negative case–control analysis. PLOS Medicine 2022, 19: e1004136. PMID: 36454733, PMCID: PMC9714718, DOI: 10.1371/journal.pmed.1004136.Peer-Reviewed Original ResearchConceptsSARS-CoV-2 infectionBooster vaccinationPrior infectionOmicron infectionPrimary vaccinationMRNA vaccinationOdds ratioAcute respiratory syndrome coronavirus 2 infectionSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectionPrior SARS-CoV-2 infectionTest-negative case-control analysisYale New Haven Health SystemTest-negative case-control studyCOVID-19 mRNA vaccinationSyndrome coronavirus 2 infectionOmicron variant infectionPrior infection statusCoronavirus 2 infectionCase-control studyCase-control analysisOdds of infectionRisk of infectionRace/ethnicityBooster dosesDate of test
2020
Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection
Borba M, Val F, Sampaio V, Alexandre M, Melo G, Brito M, Mourão M, Brito-Sousa J, Baía-da-Silva D, Guerra M, Hajjar L, Pinto R, Balieiro A, Pacheco A, Santos J, Naveca F, Xavier M, Siqueira A, Schwarzbold A, Croda J, Nogueira M, Romero G, Bassat Q, Fontes C, Albuquerque B, Daniel-Ribeiro C, Monteiro W, Lacerda M. Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection. JAMA Network Open 2020, 3: e208857. PMID: 32330277, DOI: 10.1001/jamanetworkopen.2020.8857.Peer-Reviewed Original ResearchConceptsHigh dosage groupSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectionAcute respiratory syndrome coronavirus 2 infectionLow dosage groupSyndrome coronavirus 2 infectionCoronavirus 2 infectionChloroquine diphosphateDay 13COVID-19Phase IIb clinical trialNonsevere COVID-19Secondary end pointsSevere COVID-19High-dose groupSpecific antiviral therapyTertiary care facilityIIb clinical trialCoronavirus disease 2019More heart diseaseParticipants' clinical statusAdjunctive therapyAdult patientsIll patientsPrimary outcomeAntiviral therapy